Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* RT-PCR Laboratory confirmation of COVID-19.~* Male or female aged ≥ 18 years.~* Interstitial lung change ≥ 3 judged by Lungs Lobar based scoring according to computed tomography (CT) scans.~* Hospitalized and symptomatic patients, referring one or more of the following symptoms (fever, cough, or shortness of breath), in association with (at least one): tiredness, runny nose, headache, sore throat, chills, muscle pain, or new loss of taste or smell).~* Ability to comply with test requirements and peripheral blood stem cells collection.~* The patient or legal representative agrees to participate in the study, and signs the SENTAD-COVID Study informed consent form.~Exclusion Criteria:~* Pediatric patients (aged \< 18 years).~* Diagnosis of any kind of shock.~* Organ transplants in the past 3 months.~* Patients receiving immunosuppressive therapy.~* Diagnostic of Hepatitis B Virus (HBV) infection.~* Diagnostic of Human Immunodeficiency Virus (HIV) infection or Acquired Immunodeficiency Syndrome (AIDS).~* Current diagnosis of cancer.~* History of malignancies in the past 5 years.~* Pregnant or lactating women.~* Have participated in other clinical trials in the past 3 months.~* Inability to comply with test requirements and peripheral blood stem cells collection.~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
- Group B (Type: ACTIVE_COMPARATOR): COVID-19 Standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).